View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
August 9, 2018updated 12 Jul 2022 1:13pm

Frequency treats first patients in Phase I/II trial of FX-322

Frequency Therapeutics has treated the first patients in a Phase l/ll clinical trial to investigate the safety of FX-322 for the treatment of patients with sensorineural hearing loss.

Frequency Therapeutics has treated the first patients in a Phase l/ll clinical trial to investigate the safety of FX-322 for the treatment of patients with sensorineural hearing loss.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

As part of the randomised, double-blind, placebo-controlled, multi-centre trial, FX-322 will be provided by intratympanic administration in adult patients with stable sensorineural hearing loss (SSHL) who have a medical history of either with noise exposure or sudden hearing loss.

The trial aims to enrol 24 patients at various otolaryngology clinics in the US.

The enrolled patients will receive either an FX-322 injection or a placebo in one ear with an initial follow up visit after two weeks. They will be kept under observation for the following three months.

Frequency Therapeutics clinical advisory board chairman Dan Lee said: “Hearing loss is a condition that has historically not received much attention despite the widespread nature of the issue, due in part to the difficulty of access to the inner ear environment.

“The early work done by Frequency has shown real potential for FX-322 to have a significant impact in patients with noise induced hearing loss.”

“The early work done by Frequency has shown real potential for FX-322 to have a significant impact in patients with noise induced hearing loss.

“While this is a safety study, it is an important first step to examining FX-322 in adult patients with sensorineural hearing loss.”

The Phase l/ll trial is based on Frequency’s first-in-human study completed last year, which demonstrated FX-322 to be well-tolerated and certified the potential of the drug for cochlear penetration when delivered using a standard intratympanic injection in patients scheduled for cochlear implant surgery.

FX-322 is an investigational drug candidate developed for hearing restoration, using Frequency’s Progenitor Cell Activation (PCA) regeneration platform.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena